US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% SPCX $160.57 ▼-4.19% META $720.89 ▼-0.06%
FinancialContent

Lobe Sciences Ltd (CSE:LOBE)

0.0500 UNCHANGED
Delayed Quote Updated: 2:52 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lobe Sciences Ltd

< Previous 1 2 3 Next >
News headline image
Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth
Company intends to initiate independent market-making services, expanded investor and media outreach, and add board expertise in Canadian and U.S. capital markets 
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit
● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16 ●... 
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Expands Leadership Team with New CFO Appointment
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Reports Third Quarter 2026 Financial Results
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026
From Lobe Sciences Ltd.
Via ACCESS Newswire
News headline image
Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares
Via ACCESS Newswire
News headline image
Lobe Sciences Announces Proposed Shares for Debt Transaction
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Via ACCESS Newswire
News headline image
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
Via ACCESS Newswire
News headline image
Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Via ACCESS Newswire
News headline image
Lobe Sciences Reports First Quarter 2026 Results and Highlights
Via ACCESS Newswire
News headline image
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
Via ACCESS Newswire
News headline image
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
Via ACCESS Newswire
News headline image
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Via ACCESS Newswire
News headline image
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
Via ACCESS Newswire
News headline image
Lobe Sciences Improves Balance Sheet
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
Via ACCESS Newswire
News headline image
Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
Via ACCESS Newswire
News headline image
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Via ACCESS Newswire
< Previous 1 2 3 Next >